These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 22918719)

  • 1. Metabolism of patupilone in patients with advanced solid tumor malignancies.
    Kelly KR; Zollinger M; Lozac'h F; Tan E; Mita A; Waldmeier F; Urban P; Anand S; Wang Y; Swart P; Takimoto C; Mita M
    Invest New Drugs; 2013 Jun; 31(3):605-15. PubMed ID: 22918719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mass balance study of [¹⁴C]eribulin in patients with advanced solid tumors.
    Dubbelman AC; Rosing H; Jansen RS; Mergui-Roelvink M; Huitema AD; Koetz B; Lymboura M; Reyderman L; Lopez-Anaya A; Schellens JH; Beijnen JH
    Drug Metab Dispos; 2012 Feb; 40(2):313-21. PubMed ID: 22041109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors.
    Rubin EH; Rothermel J; Tesfaye F; Chen T; Hubert M; Ho YY; Hsu CH; Oza AM
    J Clin Oncol; 2005 Dec; 23(36):9120-9. PubMed ID: 16301595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of patupilone on the pharmacokinetics and pharmacodynamics of warfarin in patients with advanced malignancies: a phase I clinical trial.
    Tsimberidou AM; Takimoto CH; Moulder S; Uehara C; Mita M; Mita A; Urban P; Tan E; Wang Y; Vining D; Kurzrock R
    Mol Cancer Ther; 2011 Jan; 10(1):209-17. PubMed ID: 21220503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors.
    Mekhail T; Masson E; Fischer BS; Gong J; Iyer R; Gan J; Pursley J; Patricia D; Williams D; Ganapathi R
    Drug Metab Dispos; 2010 Nov; 38(11):1962-6. PubMed ID: 20671097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial.
    Oehler C; Frei K; Rushing EJ; McSheehy PM; Weber D; Allegrini PR; Weniger D; Lütolf UM; Knuth A; Yonekawa Y; Barath K; Broggini-Tenzer A; Pruschy M; Hofer S
    Oncology; 2012; 83(1):1-9. PubMed ID: 22688083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study.
    Ten Bokkel Huinink WW; Sufliarsky J; Smit WM; Spanik S; Wagnerova M; Hirte HW; Kaye S; Johri AR; Oza AM
    J Clin Oncol; 2009 Jul; 27(19):3097-103. PubMed ID: 19451434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase Ib and pharmacokinetic trial of patupilone combined with carboplatin in patients with advanced cancer.
    Forster M; Kaye S; Oza A; Sklenar I; Johri A; Cheung W; Zaknoen S; Gore M
    Clin Cancer Res; 2007 Jul; 13(14):4178-84. PubMed ID: 17634546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry.
    Beumer JH; Garner RC; Cohen MB; Galbraith S; Duncan GF; Griffin T; Beijnen JH; Schellens JH
    Invest New Drugs; 2007 Aug; 25(4):327-34. PubMed ID: 17347871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mass balance, routes of excretion, and pharmacokinetics of investigational oral [
    Zhou X; Pusalkar S; Chowdhury SK; Searle S; Li Y; Ullmann CD; Venkatakrishnan K
    Invest New Drugs; 2019 Aug; 37(4):666-673. PubMed ID: 30397836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.
    Montero AJ; Kwon D; Flores A; Kovacs K; Trent JC; Benedetto P; Rocha-Lima C; Merchan JR
    Clin Cancer Res; 2016 Jul; 22(13):3209-17. PubMed ID: 26864210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of epothilone B (patupilone) in refractory lymphoma and advanced solid tumors in dogs.
    Meier V; Geigy C; Grosse N; McSheehy P; Rohrer Bley C
    J Vet Intern Med; 2013; 27(1):120-5. PubMed ID: 23205945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
    O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous low-dose infusion of patupilone increases the therapeutic index in mouse and rat tumour models.
    Becquet M; Laborde L; Texier C; Sterker D; Gschwind HP; Pfaar U; Wartmann M; O'Reilly TM; McSheehy PM
    Anticancer Drugs; 2018 Aug; 29(7):691-701. PubMed ID: 29734209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial.
    Melichar B; Casado E; Bridgewater J; Bennouna J; Campone M; Vitek P; Delord JP; Cerman J; Salazar R; Dvorak J; Sguotti C; Urban P; Viraswami-Appanna K; Tan E; Tabernero J
    Br J Cancer; 2011 Nov; 105(11):1646-53. PubMed ID: 22027708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer.
    Tsimberidou AM; Lewis N; Reid T; Burris H; Urban P; Tan EY; Anand S; Uehara C; Kurzrock R
    Cancer Chemother Pharmacol; 2011 Dec; 68(6):1507-16. PubMed ID: 21499896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma.
    Konner J; Grisham RN; Park J; O'Connor OA; Cropp G; Johnson R; Hannah AL; Hensley ML; Sabbatini P; Mironov S; Danishefsky S; Hyman D; Spriggs DR; Dupont J; Aghajanian C
    Invest New Drugs; 2012 Dec; 30(6):2294-302. PubMed ID: 22072399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patupilone in cancer treatment.
    Bystricky B; Chau I
    Expert Opin Investig Drugs; 2011 Jan; 20(1):107-17. PubMed ID: 21142807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions.
    Xia B; Heimbach T; Lin TH; He H; Wang Y; Tan E
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1567-82. PubMed ID: 22526410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors.
    Kunz PL; He AR; Colevas AD; Pishvaian MJ; Hwang JJ; Clemens PL; Messina M; Kaleta R; Abrahao F; Sikic BI; Marshall JL
    Invest New Drugs; 2012 Dec; 30(6):2364-70. PubMed ID: 22331549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.